PP 2 (AG 1879): Mechanism and Evidence Scope
2026-10-14
PP 2, also known as AG 1879, is described by APExBIO as a Src-family tyrosine-kinase inhibitor with strongest reported biochemical activity against Lck and Fyn. The product information connects Src inhibition with phosphorylation, T-cell signaling, glioma-cell proliferation and invasion, and selected rat physiological readouts, but it does not provide an identity-matched research paper, complete assay provenance, or evidence sufficient to establish broad cellular or translational selectivity.
DiscoveryProbe Metabolism Library: Evidence Scope
2026-10-14
The DiscoveryProbe™ Metabolism-related Compound Library is described by APExBIO as a 493-compound collection for metabolism-focused research. With no matched research paper available, its documented identity and intended conceptual scope can be summarized, but independent evidence for compound-level potency, selectivity, mechanisms, or biological outcomes cannot be established.
PMSF: Scope and Limits of Protease Inhibition
2026-10-13
Phenylmethanesulfonyl fluoride (PMSF) is an irreversible serine protease inhibitor used conceptually to limit proteolytic degradation in protein-extraction and immunoblotting contexts. Its selectivity is also its main boundary: PMSF does not broadly inhibit all protease classes, and supplier descriptions alone cannot establish performance across biological systems or experimental endpoints.
Phosphatase Inhibitor Cocktail: Evidence Scope
2026-10-13
APExBIO’s Phosphatase Inhibitor Cocktail (2 Tubes, 100X), SKU K1015, is documented as a two-component research reagent intended to limit endogenous phosphatase activity during protein sample handling. The available evidence is limited to supplier information; no matched research paper or independent performance data were provided.
SB 431542 in Mouse Corneal Cell Culture
2026-10-12
An original study by An et al. (2021) evaluated a multi-component culture paradigm designed to preserve mouse corneal epithelial-cell proliferation and epithelial identity. The findings support a phenotypic effect of the complete culture system, but do not establish that SB 431542 alone caused the observed changes or that the approach is clinically effective.
GSTM5, Genomic Stability and PLK1 in Breast Cancer
2026-10-12
A 2026 study combined genetic, epigenetic, transcriptomic and experimental evidence to prioritize GSTM5 as a breast-cancer susceptibility and genomic-stability candidate. Its findings support—but do not establish—a biomarker-informed hypothesis that GSTM5-low tumors may be more vulnerable to PLK1 inhibition.
Forskolin and Human Neurons in HSV-1 Latency
2026-10-11
Oh et al. developed and evaluated a human induced-pluripotent-stem-cell-derived sensory neuron model for HSV-1 latency and reactivation. The study supports the model as a scalable platform for investigating neuron-intrinsic mechanisms, while its findings do not establish Forskolin as an HSV treatment or demonstrate equivalence to infection in humans.
Wortmannin in PI3K Signaling and Cancer Research
2026-10-10
Wortmannin is a widely used research tool for interrogating PI3K-related signaling, but its irreversible action and reported activity against additional kinases require cautious interpretation. A 2026 hepatocellular carcinoma study connects FAT4 loss with PI3K/AKT activation, ferroptosis resistance, and sorafenib response, while also illustrating why pathway-level findings should not be attributed specifically to Wortmannin without direct compound evidence.
ERAD Hijacking for Transmembrane Protein Degradation
2026-10-09
Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a targeted protein degradation strategy that recruits endoplasmic-reticulum-associated degradation to remove transmembrane proteins. The study identifies desonide as a SYVN1-binding chemical warhead and reports potent PD-L1 degradation, tumor-suppression activity, and an extension of the concept to mutant huntingtin.
Sildenafil Citrate: PDE5 Signaling and Proteoforms
2026-10-09
A source-grounded overview of Sildenafil Citrate research, linking PDE5–cGMP signaling and vascular biology with recent evidence on proteoform-specific drug interactions, retinal PDE6 off-target binding, and the limits of translating vendor-reported findings into broader therapeutic conclusions.
Sildenafil Citrate: Proteoform-Aware Evidence
2026-10-08
A source-grounded overview of Sildenafil Citrate research, linking PDE5 pharmacology with recent native mass-spectrometry findings on proteoform-specific interactions. The discussion separates established study observations from supplier-reported context, compares molecular and translational evidence, and defines limits for interpreting PDE6 binding, cGMP biology, vascular signaling, and potential visual off-target effects.
Phosphatase Inhibitor Cocktail 2 in PI3K/Akt Research
2026-10-08
A source-grounded overview of how Phosphatase Inhibitor Cocktail 2 may fit conceptually into phosphoprotein studies, using canine mammary gland tumor research to distinguish supplier claims from published evidence.
IBDV VP3 Disrupts IRF7 Antiviral Signaling
2026-10-07
A 2025 study links the IBDV VP3 protein to suppression and proteasome-associated degradation of chicken IRF7, a key regulator of type I interferon responses. The findings provide a mechanistic framework for viral immune evasion while remaining primarily cell-based and requiring validation in broader infection models.
Bergeyella cardium and Floatptosis in Macrophages
2026-10-07
A 2025 Cell Discovery study identifies floatptosis, a lysosome-fusion-associated form of cytoplasmic vacuolization cell death triggered by a Bergeyella cardium variant in macrophages. The work connects this phenotype to outer membrane vesicles, barrel-like proteins, amiloride-sensitive signaling, and SLC9A9-dependent vacuole fusion while defining important boundaries for interpreting related autophagy and PI3K studies.
From Lysate Integrity to Translational Signal
2026-10-06
A mechanistic and translational perspective on how protease control can strengthen interpretation of liver-injury and phospho-signaling studies, using recent lanthanum hepatotoxicity research as a case study.